Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more ...

Greenhaven Road Capital's Q3 2025 letter analyzes a -9% return, citing no AI exposure and undervalued software holdings.

Unisys reiterates full-year non-GAAP operating profit margin guidance and advances pension strategy with annuity purchase transaction Total company revenue of ...

Welcome to this week’s edition of 18 Share Tips – our weekly selection of top ASX shares, chosen by leading analysts, that we think are worth considering. This week Toby Grimm of Baker Young, Michael ...